Tuberculosis drug development: progress, challenges, and the road ahead
- PMID: 20382086
- DOI: 10.1016/j.tube.2010.03.003
Tuberculosis drug development: progress, challenges, and the road ahead
Abstract
Tuberculosis (TB) drug development has made substantial progress in the past decade. There are currently at least ten drugs being evaluated in clinical trials. Some belong to chemical classes already employed in first- or second-line treatment regimens and are being explored for more optimized use at higher doses or in new drug combinations (rifamycins, fluoroquinolones and oxazolidinones), while others represent potential novel members of the TB drug arsenal, killing Mycobacterium tuberculosis through previously untried mechanisms of action (nitroimidazoles, diarylquinolines, ethylene diamines and pyrroles). The typical challenges of drug development are augmented in TB by the complexity of the disease, the requirement for multi-drug regimens, the relative lack of TB drug development for the past several decades, and inadequate resources being brought to bear despite the urgency of the global medical need. Yet in the face of these challenges, for the first time in history, there is a robust enough pipeline of drugs in development to potentially enable identification of a novel, three-drug regimen capable of curing patients in three months or less, whether they are infected with a strain of M. tuberculosis sensitive or resistant to the current first and second-line drugs. Realizing this potential will require innovation, persistence, cooperation and resources. A fine balance will need to be achieved between protecting novel drugs so that resistance to them doesn't develop and ensuring the regimens are low in cost, readily available, and adopted by healthcare systems and providers.
Copyright 2010 Elsevier Ltd. All rights reserved.
Similar articles
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes.Curr Opin Pulm Med. 2010 May;16(3):186-93. doi: 10.1097/MCP.0b013e328337580c. Curr Opin Pulm Med. 2010. PMID: 20216421 Review.
-
[Frontier of mycobacterium research--host vs. mycobacterium].Kekkaku. 2005 Sep;80(9):613-29. Kekkaku. 2005. PMID: 16245793 Japanese.
-
Challenges, successes and hopes in the development of novel TB therapeutics.Future Med Chem. 2009 Jul;1(4):749-56. doi: 10.4155/fmc.09.53. Future Med Chem. 2009. PMID: 21426037 Review.
-
Mycobacterium tuberculosis: drug resistance and future perspectives.Future Microbiol. 2009 Jun;4(5):597-614. doi: 10.2217/fmb.09.20. Future Microbiol. 2009. PMID: 19492969 Review.
Cited by
-
Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis.Tuberculosis (Edinb). 2014 May;94(3):187-96. doi: 10.1016/j.tube.2014.01.006. Epub 2014 Feb 7. Tuberculosis (Edinb). 2014. PMID: 24629635 Free PMC article. Clinical Trial.
-
Optimization of Thiazolidone Scaffolds Using Pocket Modeling for Development of Potential Secretory System Inhibitors of Mycobacterium tuberculosis.Turk J Pharm Sci. 2019 Jun;16(2):196-205. doi: 10.4274/tjps.galenos.2018.12599. Epub 2019 Mar 27. Turk J Pharm Sci. 2019. PMID: 32454714 Free PMC article.
-
Moxifloxacin and gatifloxacin for initial therapy of tuberculosis: a meta-analysis of randomized clinical trials.Emerg Microbes Infect. 2016 Feb 24;5(2):e12. doi: 10.1038/emi.2016.12. Emerg Microbes Infect. 2016. PMID: 26905025 Free PMC article.
-
Recent Developments in Drug Delivery for Treatment of Tuberculosis by Targeting Macrophages.Adv Ther (Weinh). 2022 Jun;5(6):2100193. doi: 10.1002/adtp.202100193. Epub 2022 Mar 9. Adv Ther (Weinh). 2022. PMID: 36203881 Free PMC article.
-
Longitudinal Model-Based Biomarker Analysis of Exposure-Response Relationships in Adults with Pulmonary Tuberculosis.Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0179420. doi: 10.1128/AAC.01794-20. Epub 2021 Jul 12. Antimicrob Agents Chemother. 2021. PMID: 34252302 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous